Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
2012

Using VEGF Inhibitors to Treat Ovarian Cancer

publication Evidence: moderate

Author Information

Author(s): Afshin Amini, Masoumi Moghaddam Samar, Morris David L., Pourgholami Mohammad H.

Primary Institution: The University of New South Wales

Hypothesis

Can targeting vascular endothelial growth factor (VEGF) improve treatment outcomes for ovarian cancer?

Conclusion

VEGF inhibitors show promise in treating ovarian cancer, but challenges such as resistance and side effects remain significant.

Supporting Evidence

  • VEGF plays a crucial role in the progression of ovarian cancer.
  • VEGF inhibitors have shown effectiveness in preclinical and clinical studies.
  • Resistance to anti-VEGF therapy is a common issue in ovarian cancer treatment.

Takeaway

Doctors are trying to use special medicines that block a substance called VEGF to help treat ovarian cancer, which is a very serious disease.

Methodology

The article reviews various studies on the role of VEGF in ovarian cancer and the effectiveness of VEGF inhibitors.

Limitations

The study highlights the lack of predictive markers for treatment efficacy and the potential for resistance to therapy.

Digital Object Identifier (DOI)

10.1155/2012/540791

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication